The team turned to Ossium Health, a San Francisco–based biotech startup that is collecting bone marrow from recently deceased organ donors, cryopreserving it, and building a bank of frozen bone ...

Ossium is currently conducting a clinical study (PRESERVE I) to evaluate the safety and effectiveness of its organ donor-derived bone marrow in patients with hematopoietic malignancies.

Ossium Health, a clinical-stage bioengineering company that built a first-of-its-kind organ donor-derived bone marrow bank to deploy hematopoietic stem cells for blood cancer treatment, today ...

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening blood and immune ...

Ossium’s programme offers cryopreserved bone marrow sourced from deceased organ donors. Bone marrow transplants replace damaged blood cells with healthy ones in patients suffering from blood ...

Ossium Health, a clinical-stage bioengineering company with a first-of-its-kind bone marrow banking platform for processing and deploying hematopoietic stem cells and stem cell-based therapies ...

Ossium works with Organ Procurement Organizations (OPOs) that represent just over half of all organ donors in the U.S. to recover viable vertebral bodies for bone marrow and orthopedic donations.

The bioengineering company Ossium Health has created a new program that offers deep-frozen bone marrow from deceased organ donors -- and a Michigan woman has received the first transplant.

Ossium’s $63M Series B is the latest financing for the five-year-old company which has raised a total of $74M. Ossium’s research has also been supported by more than $6M in NIH grants ...

Speaking to Pharmaceutical Technology, Ossium’s CEO Kevin Caldwell explained that the bone marrow is cryopreserved and available for immediate shipment on-demand, eliminating the time necessary ...

Photo: Ossium Health Inc. Ossium Health Inc. has raised $63 million in venture capital to pursue a goal of using stem cells to treat leukemia and other illnesses.

Fibrogenesis imperfecta ossium is a rare disorder of bone usually characterized by marked osteopenia and associated with variable osteoporosis and osteosclerosis, changing over time. Histological ...